Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Get Instant Summarized Text (Gist) First-generation GLP-1 receptor agonists reduce the risk of obesity-related cancers independently of weight loss, showing a 41% lower relative risk compared to ...

Data were included for 262 adults with a body mass index greater than or equal to 27kg/m2 who were initiated on liraglutide or semaglutide. HealthDay News — Glucagon-like peptide-1 receptor ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...

after ablation if they are taking a glucagon-like peptide 1 (GLP-1) receptor agonist vs another diabetes drug, according to an analysis of matched cohorts with 3 years of follow-up. The study was ...